Table I.
Comparison of clinicopathological data between patients treated with Hydrogen gas + Nivolumab and Nivolumab only.
| Factor | Hydrogen gas + Nivolumab (n=42) | Nivolumab only (n=14) | P-value |
|---|---|---|---|
| Age | 63.6±12.2 | 62.7±8.68 | NS |
| Sex | NS | ||
| Male | 14 | 8 | |
| Female | 28 | 6 | |
| T factor | NS | ||
| T1 | 2 | 1 | |
| T2 | 10 | 3 | |
| T3 | 16 | 5 | |
| T4 | 8 | 4 | |
| Tx | 6 | 1 | |
| N factor | NS | ||
| N0 | 6 | 2 | |
| N1 | 12 | 2 | |
| N2 | 6 | 3 | |
| N3 | 8 | 3 | |
| Nx | 10 | 4 | |
| M factor | NS | ||
| M0 | 0 | 0 | |
| M1a | 30 | 10 | |
| M1b | 12 | 4 | |
| Histology | NS | ||
| Adenocarcinoma | 30 | 10 | |
| SCC | 12 | 4 |
NS, Not Significant; T factor, Primary Tumor; N factor, Regional Lymph Node; M factor, Distant Metastasis; M1a, Contra-lateral lung metastasis, pleural nodules, malignant pleural effusion; M1b, Distant metastasis to organs other than lungs; SCC, Squamous Cell Carcinoma.